Updated just now · Live
Stock analysis, price data, and AI-powered insights for Spyre Therapeutics Inc (SYRE).
Spyre Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for SYRE.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). SYRE Stock Intelligence Report. [stoxpulse.com/stocks/syre]
Disclaimer: The information on this page about Spyre Therapeutics Inc (SYRE) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Spyre Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Spyre Therapeutics, Inc. Announces Closing of Publ...
5d ago
This Cloudflare Analyst Turns Bullish; Here Are To...
6d ago
StoxPulse AI results for SYRE: Pulse Score 51.5/100. Primary sentiment trends from 14 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$5.76B
P/E Ratio
—
EPS
—
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
This Cloudflare Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Reported Earlier, Spyre Therapeutics Prices Upsized Public Offering Of 6.5M Common Shares At $62.00 Per Share For Gross Proceeds Of $403.0M
Spyre Therapeutics announces pricing of upsized $403 million public offering of common stock
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $90
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $80
This Monday.Com Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Apple To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday